Aim: To determine the prevalence of chromosomal abnormalities in couples with reproductive disorders. Methods: A retrospective study was performed in 939 Mexican couples with reproductive disorders (542 with recurrent fetal loss, 356 with malformed/stillborn children, and 41 with sterility) whose karyotype was established on GTG-banded metaphases. Results: A chromosomal aberration was detected in one partner of 52 couples, including a double translocation carrier; therefore, the prevalence of chromosomally abnormal couples was 5.5%; 31 couples with recurrent fetal loss (31/542, 5.7%), 15 with malformed/stillborn children (15/356, 4.2%), and 6 with sterility (6/41, 14.6%). There were 43 couples with structural rearrangements (29 reciprocal translocations, 10 robertsonian translocations, 2 inversions, 1 insertion, and 1 ring) and 9 with gonosomal aneuploidies. The affected partner was female in 28 (53.8%) and male in 24 (46.2%) couples. In addition, 17 couples (1.8%) with the structural variant inversion 9qh were detected. Conclusion: The prevalence of chromosomal abnormalities found in our sample is consistent with figures described in several populations around the world.

This content is only available via PDF.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.